Aarhus University Seal / Aarhus Universitets segl

Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Standard

Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety. / Breining, Peter; Frølund, Anne Lier; Højen, Jesper Falkesgaard; Gunst, Jesper Damsgaard; Staerke, Nina B; Sædder, Eva Aggerholm ; Cases-Thomas, Manuel; Little, Paul; Nielsen, Lars Peter; Søgaard, Ole S; Kjolby, Mads.

I: Basic & Clinical Pharmacology & Toxicology, Bind 128, Nr. 2, 02.2021, s. 204-212.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{8acc9e191f584b6faa737c16046456fc,
title = "Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety",
abstract = "The coronavirus responsible for COVID-19, SARS-CoV-2, utilizes a viral membrane spike protein for host cell entry. For the virus to engage in host membrane fusion, SARS-CoV-2 utilizes the human transmembrane surface protease, TMPRSS2, to cleave and activate the spike protein. Camostat mesylate, an orally available well-known serine protease inhibitor, is a potent inhibitor of TMPRSS2 and has been hypothesized as a potential antiviral drug against COVID-19. In vitro human cell and animal studies have shown that camostat mesylate inhibits virus-cell membrane fusion and hence viral replication. In mice, camostat mesylate treatment during acute infection with influenza, also dependent on TMPRSS2, leads to a reduced viral load. The decreased viral load may be associated with an improved patient outcome. Because camostat mesylate is administered as an oral drug, it may be used in outpatients as well as inpatients at all disease stages of SARS-CoV-2 infection if it is shown to be an effective antiviral agent. Clinical trials are currently ongoing to test whether this well-known drug could be repurposed and utilized to combat the current pandemic. In the following, we will review current knowledge on camostat mesylate mode of action, potential benefits as an antiviral agent and ongoing clinical trials.",
author = "Peter Breining and Fr{\o}lund, {Anne Lier} and H{\o}jen, {Jesper Falkesgaard} and Gunst, {Jesper Damsgaard} and Staerke, {Nina B} and S{\ae}dder, {Eva Aggerholm} and Manuel Cases-Thomas and Paul Little and Nielsen, {Lars Peter} and S{\o}gaard, {Ole S} and Mads Kjolby",
note = "{\textcopyright} 2020 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).",
year = "2021",
month = feb,
doi = "10.1111/bcpt.13533",
language = "English",
volume = "128",
pages = "204--212",
journal = "Basic & Clinical Pharmacology & Toxicology",
issn = "1742-7843",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "2",

}

RIS

TY - JOUR

T1 - Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

AU - Breining, Peter

AU - Frølund, Anne Lier

AU - Højen, Jesper Falkesgaard

AU - Gunst, Jesper Damsgaard

AU - Staerke, Nina B

AU - Sædder, Eva Aggerholm

AU - Cases-Thomas, Manuel

AU - Little, Paul

AU - Nielsen, Lars Peter

AU - Søgaard, Ole S

AU - Kjolby, Mads

N1 - © 2020 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

PY - 2021/2

Y1 - 2021/2

N2 - The coronavirus responsible for COVID-19, SARS-CoV-2, utilizes a viral membrane spike protein for host cell entry. For the virus to engage in host membrane fusion, SARS-CoV-2 utilizes the human transmembrane surface protease, TMPRSS2, to cleave and activate the spike protein. Camostat mesylate, an orally available well-known serine protease inhibitor, is a potent inhibitor of TMPRSS2 and has been hypothesized as a potential antiviral drug against COVID-19. In vitro human cell and animal studies have shown that camostat mesylate inhibits virus-cell membrane fusion and hence viral replication. In mice, camostat mesylate treatment during acute infection with influenza, also dependent on TMPRSS2, leads to a reduced viral load. The decreased viral load may be associated with an improved patient outcome. Because camostat mesylate is administered as an oral drug, it may be used in outpatients as well as inpatients at all disease stages of SARS-CoV-2 infection if it is shown to be an effective antiviral agent. Clinical trials are currently ongoing to test whether this well-known drug could be repurposed and utilized to combat the current pandemic. In the following, we will review current knowledge on camostat mesylate mode of action, potential benefits as an antiviral agent and ongoing clinical trials.

AB - The coronavirus responsible for COVID-19, SARS-CoV-2, utilizes a viral membrane spike protein for host cell entry. For the virus to engage in host membrane fusion, SARS-CoV-2 utilizes the human transmembrane surface protease, TMPRSS2, to cleave and activate the spike protein. Camostat mesylate, an orally available well-known serine protease inhibitor, is a potent inhibitor of TMPRSS2 and has been hypothesized as a potential antiviral drug against COVID-19. In vitro human cell and animal studies have shown that camostat mesylate inhibits virus-cell membrane fusion and hence viral replication. In mice, camostat mesylate treatment during acute infection with influenza, also dependent on TMPRSS2, leads to a reduced viral load. The decreased viral load may be associated with an improved patient outcome. Because camostat mesylate is administered as an oral drug, it may be used in outpatients as well as inpatients at all disease stages of SARS-CoV-2 infection if it is shown to be an effective antiviral agent. Clinical trials are currently ongoing to test whether this well-known drug could be repurposed and utilized to combat the current pandemic. In the following, we will review current knowledge on camostat mesylate mode of action, potential benefits as an antiviral agent and ongoing clinical trials.

U2 - 10.1111/bcpt.13533

DO - 10.1111/bcpt.13533

M3 - Review

C2 - 33176395

VL - 128

SP - 204

EP - 212

JO - Basic & Clinical Pharmacology & Toxicology

JF - Basic & Clinical Pharmacology & Toxicology

SN - 1742-7843

IS - 2

ER -